Medicine Overview of Linaglip 5mg Tablet
Introduction
Linaglip 5 is a medicine used to treat type 2 diabetes mellitus. It is used together with a healthy diet and regular exercise to control blood sugar levels. This helps to prevent serious complications of diabetes like kidney damage and blindness. Linaglip 5 is normally prescribed when diet and exercise alone or other medicines do not prove sufficient to control your blood sugar level. Your doctor may prescribe it alone or along with other diabetes medicines. It can be taken with or without food. The dose will depend on your condition, and blood sugar levels. Therefore, you should use it
Uses of Linaglip 5
- Type 2 diabetes mellitus
Side effects of Linaglip 5
Common
- Hypoglycaemia (low blood sugar level) in combination with insulin or sulphonylurea
- Headache
- Nasopharyngitis (inflammation of the throat and nasal passages)
- Cough
- Allergic reaction
How to use Linaglip 5
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Linaglip 5 may be taken with or without food, but it is better to take it at a fixed time.
How Linaglip 5 works
Linaglip 5 is an antidiabetic medication. It works by increasing the release of insulin from the pancreas and decreasing the hormones that raise blood sugar levels. This reduces the fasting and postmeal sugar levels.
Quick Tips
-
Linaglip 5 should be taken at the same time every day since this helps you remember to take it.
-
It may cause hypoglycemia (low blood sugar level) when used with other antidiabetic medicines, alcohol or if you delay or miss a meal.
-
Always carry some sugary food or fruit juice with you in case you experience hypoglycemia symptoms such as cold sweats, cool pale skin, tremor and anxiety.
-
Be careful while driving or operating machinery until you know how Linaglip 5 affects you.
-
Inform your doctor if you notice joint pains or develop symptoms such as stomach pain, nausea and/or vomiting.
Brief Description
Indication
Type 2 Diabetes Mellitus
Administration
May administer with or without food
Adult Dose
Oral
Type 2 diabetes mellitus
Adult: 5 mg once daily.
Type 2 diabetes mellitus
Adult: 5 mg once daily.
Indicated for adults with diabetes mellitus type II along with diet and exercise to lower blood sugar; may be used as monotherapy or in combination with other common antidiabetic medications including metformin, sulfonylurea, pioglitazone, or insulin.
Elderly: No dose adjustment is necessary based on age.
Hepatic or renal impairment: No dosage adjustment required.
Child Dose
Safety and efficacy not established
Renal Dose
Renal Impairment: No dose adjustment.
Contraindication
Patients with a history of a hypersensitivity reaction to linagliptin, such as urticaria, angioedema, or bronchial hyperreactivity. Type 1 DM. Treatment of diabetic ketoacidosis.
Mode of Action
Dipeptidyl peptidase 4 (DPP-4) inhibitor; increases and prolongs incretin hormone activity which is inactivated by DPP-4 enzyme.
Incretins regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and reducing glucagon secretion from pancreatic alpha cells .
Precaution
Concomitant use w/ sulphonylureas which are known to cause hypoglycemia; dose reduction of sulphonylureas may be considered. May affect ability to drive or operate machinery. Childn. Elderly >75 yr. Pregnancy & lactation.
Lactation: Unknown whether distributed in breast milk; caution advised
Side Effect
1-10%
Nasopharyngitis (4.3%),Hyperlipidemia (2.8%; with pioglitazone),Cough (2.4%; with metformin and sulfonylurea),Hypertriglyceridemia (2.4%; with sulfonylurea),Weight gain (2.3%; with pioglitazone),
Hypoglycemia 7.6% overall incidence, 22.9% incidence compared with placebo plus metformin and a sulfonylurea
Incidence similar to placebo with monotherapy or combined with metformin or pioglitazone
Nasopharyngitis (4.3%),Hyperlipidemia (2.8%; with pioglitazone),Cough (2.4%; with metformin and sulfonylurea),Hypertriglyceridemia (2.4%; with sulfonylurea),Weight gain (2.3%; with pioglitazone),
Hypoglycemia 7.6% overall incidence, 22.9% incidence compared with placebo plus metformin and a sulfonylurea
Incidence similar to placebo with monotherapy or combined with metformin or pioglitazone
Interaction
Increased risk of hypoglycaemia when used w/ an insulin secretagogue (e.g. sulfonylurea) or insulin. Plasma concentration of linagliptin may be decreased by strong inducers of P-glycoprotein (e.g. rifampicin) and may be increased by strong P-glycoprotein inhibitors (e.g. ritonavir).
Reviews
Clear filtersThere are no reviews yet.